Browse the corpus

Malignant melanoma is a potentially life-threatening skin cancer and ranks as the fifth most common cancer in men and sixth in women. Among its subtypes, cutaneous malignant melanoma (CMM) is the most frequently diagnosed and accounts for the majority of melanoma-related morbidity and mortality. Early recognition and accurate staging are critical to guide treatment, predict prognosis, and improve survival outcomes. As incidence rates continue to rise, particularly among fair-skinned populations, the need for timely, evidence-based evaluation has become increasingly important. This educational activity provides a comprehensive overview of the American Joint Committee on Cancer (AJCC) 8th edition staging system, highlighting key updates and their clinical implications. Learners will examine current best practices for screening, biopsy techniques, imaging, and treatment selection, as outlined by national and international guidelines. Topics include appropriate surgical margins, the role of sentinel lymph node biopsy, and indications for adjuvant therapies, including immunotherapy for high-risk disease. The course also underscores the value of coordinated, interdisciplinary care involving dermatology, surgical oncology, medical oncology, radiology, and pathology. By participating in this activity, healthcare professionals will enhance their ability to accurately stage disease, implement evidence-based management strategies, and collaborate effectively within interprofessional teams to optimize care for patients with cutaneous malignant melanoma. Objectives: Interpret epidemiological data to understand current trends in the incidence and prevalence of cutaneous melanoma in the United States. Compare NCCN, Cancer Council Australia, AAD, and ESMO guideline recommendations for diagnosing cutaneous malignant melanoma. Identify guideline-based recommendations for genetic counseling evaluation in patients with a personal or family history of cutaneous malignant melanoma. Coordinate post-treatment surveillance strategies as an interprofessional team to ensure comprehensive long-term management of patients with cutaneous malignant melanoma. Access free multiple choice questions on this topic.

Cutaneous melanoma is the fifth most common cancer diagnosis in the United States, and the incidence continues to increase with a projected 110000 new cases in the year 2030 compared to around 65000 new cases in 2011.[1] Around 84% of the cases present with localized disease, 9% with involvement of regional lymph nodes, and 4% present with distant metastases at diagnosis.[2] Evidence-based clinical guidelines from different professional societies are available to aid in the accurate diagnosis and management of malignant melanoma. In this article, we review the staging of cutaneous malignant melanoma and provide a summary of the clinical guidelines from the American Association of Dermatology (AAD), European Society of Medical Oncology (ESMO), National Comprehensive Cancer Network (NCCN), and Cancer Council Australia for the management of cutaneous malignant melanoma. All clinical guidelines adopt clinical staging based on the eighth edition of Tumor, Node, Metastases (TNM) staging of the American Joint Committee on Cancer (AJCC).[3] AAD guidelines apply to clinical stage 0 to stage IIC and were last updated in January 2019.[4] ESMO,  NCCN guidelines apply to all stages of cutaneous malignant melanoma.[5][2] ESMO guidelines were last updated in December 2019, NCCN guidelines are continuously updated, while Australian guidelines were last updated in July 2020.[6]

Interprofessional care is essential in the management of cutaneous malignant melanoma. A collaborative approach involving dermatologists, pathologists, surgical, medical, and radiation oncologists, genetic counselors, advanced practitioners, social workers, pharmacists, and the patient’s primary care provider ensures comprehensive, patient-centered care across the continuum. Each member of the interprofessional team contributes unique expertise to optimize early detection, accurate staging, treatment selection, surveillance, and psychosocial support. The NCCN guidelines recommend multidisciplinary tumor board review for patients with extensive nodal involvement or disseminated disease to guide complex decision-making. Similarly, the Cancer Council Australia (CCA) recommends multidisciplinary care for all patients with stage III and IV cutaneous melanoma. These team-based strategies enhance clinical outcomes by ensuring timely referrals, coordinated follow-up, and integration of systemic therapy, radiation, surgical, and supportive care services. By embracing interprofessional communication and care coordination, healthcare teams can reduce delays, minimize errors, and support shared decision-making that respects patient values. This model of care aligns with the principles of interprofessional continuing education (IPCE) and reflects the growing recognition that high-quality cancer care depends on the seamless collaboration of all healthcare team members.